Enveric Biosciences announced that it has received a notice of allowance from the United States Patent and Trademark Office, or USPTO, for a patent application pertaining to its EVM301 Series of molecules being developed as potential treatments for mental health disorders.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ENVB:
